Biotechnology

Monday Feb 06, 2023 - 11:15 am

MetAlert, Inc. (MLRT) – Developing New and Practical GPS Tracking and Other Health Tech Solutions for Real-World Caregivers and Businesses

MetAlert, a developer of personal protective medical equipment and supplies, owes much of its growth to acting on feedback from real-world caregivers who use its products for the monitoring and tracking of vulnerable patients This connection with caregivers has yielded advanced products such as the award-winning, multi-patented GPS SmartSole, Invisabelt, Take-Along Tracker, and Rover Tracker, among others Attention to consumers has also led to its…

Monday Feb 06, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company is developing nanosized antibodies (“NanoAbs”) addressing large market diseases underserved by current treatments, with its lead candidate targeting COVID-19 The FDA recently revoked the sole authorization of a COVID prophylactic, Evusheld, citing the inability of the monoclonal antibody cocktail to neutralize emerging subvariants of the Omicron variant BiondVax’s lead…

Thursday Feb 02, 2023 - 9:00 am

MetAlert, Inc. (MLRT) Patient Tracking Technology To Gain User Access in Sweden’s Cognitive Care Centers

GPS-enabled location device developer MetAlert provides geographical tracking technology that is discrete and functional through shoe inserts that provide data connectivity to cognitive patient caregivers MetAlert announced in January that it is expanding the reach of its SmartSole flagship product through an agreement with Sweden’s government that was established by distribution partner Posifon AB Government agencies across Europe and in the United States have recognized…

Monday Jan 30, 2023 - 11:15 am

MetAlert, Inc. (MLRT) Market for Self-actualized Wellness Grows

Wearable wellness technology innovator MetAlert is revitalizing its brand and increasing its product and services portfolio through M&A and other corporate developments designed to improve the company’s healthcare profile The mortality associated with chronic disease can be ameliorated with the use of wearable devices, along with other healthful practices, and the use of wearable wellness technology is expected to continue at an increasing pace More…

Monday Jan 30, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use…

Thursday Jan 26, 2023 - 9:45 am

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R) The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police…

Thursday Jan 26, 2023 - 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical

SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions Data collection from all study groups expected by April 2023 SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics Silo Pharma (NASDAQ: SILO),…

Tuesday Jan 24, 2023 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space

Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO With heart disease consistently being the leading cause of death in the United States (https://ibn.fm/kDLwz), companies such as HeartBeam (NASDAQ: BEAT) that are…

Monday Jan 23, 2023 - 10:30 am

MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

MetAlert’s CEO, Patrick Bertagna, while appearing in an interview presented by Sequire Spotlight and hosted by Carmel Fisher, expressed his optimism for the new year while also sharing the company’s recent progress He discussed the company’s core objective- increasing the quality of life, and longevity of people living with Alzheimer’s, dementia, and autism (“ADA”) Bertagna also hinted at potential acquisitions by the company, attributing it…

Thursday Jan 19, 2023 - 9:00 am

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

MetAlert recently signed a Letter of Intent to acquire Florida-based TrakTec in a cash and stock deal worth $4.5 million TrakTec manufactures and sells affordable location awareness technology solutions for consumer, enterprise, and government applications The planned acquisitions will bring on board synergistic and complementary technologies that fit in with MetAlert’s subscription model and existing suite of location-sensitive and tracking solutions The acquisition is also…

Tuesday Jan 17, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where…

Friday Jan 13, 2023 - 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an…

Thursday Jan 12, 2023 - 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions…

Tuesday Jan 10, 2023 - 12:00 pm

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100,…

Tuesday Jan 10, 2023 - 10:30 am

MetAlert, Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space

MetAlert is a pioneer in location-sensitive health monitoring devices and wearable technology products targeting the Alzheimer’s, Dementia, and Autism (“ADA”) market The company is looking to provide cutting-edge telehealth technologies and is continuously working to roll out improved and more innovative products for its users Its SmartSole(R) product facilitates discreet tracking and remote monitoring of ADA patients The company has also launched SmartSole plus(R), which…

Friday Jan 06, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform

BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-COVID-19 NanoAb candidate resulted in milder and shorter illness The company also received support and advice from the Paul Ehrlich Institute (“PEI”), which are viewed as key toward…

Friday Jan 06, 2023 - 9:45 am

MetAlert, Inc. (MLRT) – Offering More Than Location-Sensitive Health Monitoring Devices

The CDC estimates that by 2060, over 14 million Americans may be diagnosed with Alzheimer’s, up from the current 6.5 million In a surprising study, presented at the 2022 Alzheimer’s Association International Conference, it was noted that this rise could be largely attributed to people’s intake of ultra-processed foods, which was linked to a higher risk of dementia Of the 10,000 participants who took part…

Wednesday Jan 04, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements

BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”) The technology is exclusively licensed from the prestigious Max Planck Institute for Multidisciplinary Sciences and the…

Wednesday Jan 04, 2023 - 9:00 am

MetAlert, Inc. (MLRT) Recognizes Link Between Cognition in Aging Population and Use of Hearing Aids

MetAlert has, since its inception, sought to offer quality-of-life improvements to patients and caregivers dealing with Alzheimer’s, dementia, and autism (“ADA”) This focus has led to the company offering products and services within the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring Also important is MetAlert’s offering of hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled…

Wednesday Dec 28, 2022 - 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trials The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3% The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed…

Wednesday Dec 28, 2022 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers CNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM…

Tuesday Dec 27, 2022 - 10:30 am

Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up…

Wednesday Dec 21, 2022 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”) The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient This key data enables physicians to assess whether symptoms may be the result of a heart attack HeartBeam’s (NASDAQ: BEAT) small, portable, easy-to-use heart-attack detection solution was the focus of…

Tuesday Dec 20, 2022 - 11:15 am

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

Jupiter Wellness has announced that the “FDA of India” has approved its topical treatment for psoriasis and vitiligo, with a market launch to follow The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026 JW-500, a topical treatment for female sexual wellness, is…

Monday Dec 19, 2022 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection

BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch Projections for global smartwatch and wearables medical-device markets show consistent upward growth In a world where an estimated 202.6 million people use smartwatches (https://ibn.fm/zb66P), the ability to harness the power of…

Friday Dec 16, 2022 - 11:15 am

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

Ludlow Research ups price target for MetAlert, leading developer of location-sensitive health monitoring devices and wearable technology products, anticipating target between $1 and $1.25 per share MetAlert announced the elimination of all its toxic convertible notes from its balance sheet, which now provides increased stability to its public float The company also shared improved guidance to its NFC operations while also announcing the launch of…

Wednesday Dec 14, 2022 - 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the…

Tuesday Dec 13, 2022 - 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42…

Monday Dec 12, 2022 - 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels CNS is building upon prior clinical trial outcomes with its global…

Friday Dec 09, 2022 - 9:00 am

MetAlert Inc. (MLRT) to Begin Marketing and Distribution of RoomMate(TM) in the U.S., Canada, and the U.K., following Partnership with Sensio Group

MetAlert recently announced the signing of an LOI with Sensio Group for the marketing and distribution of RoomMate, a 3D Infrared supervision product with a fall detection automated monitoring system The company has set out to solve problems unique to individuals afflicted with ADA by creating devices specific to their use cases, and RoomMate is one such product, promising effective remote patient monitoring while maintaining…

Monday Dec 05, 2022 - 9:45 am

MetAlert Inc. (MLRT) Announces Canadian Distributor Launch of Award-Winning 4G GPS SmartSole Medical Monitoring Device for Alzheimer’s, Dementia, and Autism

ARPA-H is investing a billion dollars to encourage cutting-edge research for Alzheimer's, supporting bold ideas to pursue and drive new biomedical breakthroughs The Department of Health and Human Services is investing in research and technology to help keep Alzheimer's patients in their homes longer, train caregivers to support them, and educate Americans about Alzheimer's early warning signs – all of which MetAlert provides products and…

Thursday Dec 01, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

Odyssey is set to hold its Annual Meeting of Stockholders on January 12, 2023 The meeting promises an excellent podium to update shareholders on the company’s progress throughout the 2022 calendar year as well as its plans for the future Odyssey has so far achieved vital milestones such as progress in its ONP-002 novel compound on the treatment of concussions, patent protection filing for its…

Tuesday Nov 29, 2022 - 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell The global market…

Tuesday Nov 29, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need” Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury Odyssey is…

Monday Nov 28, 2022 - 9:00 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy,…

Wednesday Nov 23, 2022 - 11:15 am

MetAlert Inc. (MLRT) Is ‘One to Watch’

MetAlert’s management team is highly experienced (several previous exits) in the tech, apparel, and wearable medical device industries, with significant management ownership (70%+) in MLRTThe company operates in a large and growing global market in terms of potential revenue ($20-$50+ per month) and number of users (34+ million), with a potential impact on hundreds of millionsThe recent pandemic created an emphasis on health monitoring, especially…

Wednesday Nov 23, 2022 - 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer

New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnershipsDr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical SchoolDr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors In a display of its commitment to offering innovative, high-quality products and services,…

Tuesday Nov 22, 2022 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during…

Tuesday Nov 22, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumorsCNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBMBerubicin is a novel anthracycline and the first to appear to cross the blood-brain barriermag8The global…

Monday Nov 21, 2022 - 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank CompetitionCompany’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosisHeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions